TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BDFBVT43
Issuer Name
OXFORD BIOMEDICA PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
Institut Merieux SA
City of registered office (if applicable)
Lyon
Country of registered office (if applicable)
France
4. Details of the shareholder
| Name | City of registered office | Country of registered office |
| Natixis | Paris | France |
5. Date on which the threshold was crossed or reached
19-Jun-2024
6. Date on which Issuer notified
19-Jun-2024
7. Total positions of person(s) subject to the notification obligation
|
| % of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer |
| Resulting situation on the date on which threshold was crossed or reached | 10.934389 | 0.000000 | 10.934389 | 11,510,481 |
| Position of previous notification (if applicable) | 6.151995 | 0.000000 | 6.151995 | 6149374 |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
| Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
| GB00BDFBVT43 | 11,510,481 | 0 | 10.934389% | 0.000000 |
| Sub Total 8.A | 11,510,481 | 10.934389% | ||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
| Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
|
| | | | |
| Sub Total 8.B1 | | | | |
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
| Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
|
| | | | | |
| Sub Total 8.B2 | | | | ||
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
| Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
| Institut Merieux SA | TSGH SAS | 10.934389% | 0.000000 | 10.934389% |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
TSGH SAS (a wholly owned subsidiary of Institut Merieux SA) holds the shares in Oxford Biomedica Plc through a securities account of the French corporate and investment bank, Natixis (the ''Shareholder''). Institut Merieux SA has control and discretion over the voting rights attaching to the shares of Oxford Biomedica Plc, which are held by the Shareholder, through its ownership of the equity of TSGH SAS.
12. Date of Completion
| 19 June 2024 |
13. Place Of Completion
United Kingdom
| Contact name: | Natalie Walter |
| Contact phone number: | 01865 783 000 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
